Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today

By Cory Renauer – Aug 10, 2021 at 10:56AM

Key Points

  • Fulcrum Therapeutics is pioneering a new method of new drug discovery that produced its lead candidate, FTX-6058.
  • Healthy volunteers who received a once-daily dose of FTX-6058 showed signs that strongly suggest this drug will provide a meaningful benefit for people with sickle cell disease.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A positive trial readout suggests the company's new drug discovery engine has more potential than expected.

What happened

Shares of Fulcrum Therapeutics (FULC 0.15%), an early clinical-stage biopharmaceutical company, are rocketing higher after an encouraging clinical trial readout. Investors excited about the company's sickle-cell disease candidate pushed the stock 76% higher as of 10:35 a.m. EDT on Monday.

So what 

This morning Fulcrum Therapeutics shared data from the company's first clinical trial. The phase 1 study with healthy volunteers showed the company's lead candidate, FTX-6058, was well tolerated and likely to be an effective treatment for people born with sickle cell disease (SCD) and other hemoglobin-related disorders.

Smiling scientist in a laboratory.

Image source: Getty Images.

Normally, healthy adult patient data doesn't drive biotech stocks this powerfully. All eyes were on this readout because it could be the first of many for Fulcrum Medicines. The biotech employs machine learning techniques to find new drug targets, which is much easier said than done.

Healthy volunteers who swallowed FTX-6058 tablets once a day for two weeks showed significant signs of fetal hemoglobin (HbF) production. Blood cells designated to carry lots of HbF increased more than fourfold for volunteers who received the highest dosage.

Now what

The root cause of SCD is unstable hemoglobin, and gene therapies that train bone marrow to produce HbF have been shown to work for the most severe forms of the disease. Most notably, a single administration of CTX001 from collaboration partners CRISPR Therapeutics and Vertex Pharmaceuticals has eliminated severe SCD patients' reliance on blood transfusions for years at a time following a single administration.

Unfortunately for Vertex and CRISPR, single administration treatments are a lot more difficult to sell than drugs like FTX-6058, which pharmacists could eventually dispense as a simple pill to be taken once daily. Since Fulcrum Therapeutics doesn't need to prove super long-term efficacy the way CTX001 does, its development timeline will be much shorter. 

Fulcrum intends to begin treating sickle cell patients in the fourth quarter of 2021. If they can produce enough HbF to reduce their reliance on blood transfusions, this biotech stock will rocket higher still.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends CRISPR Therapeutics. The Motley Fool recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fulcrum Therapeutics, Inc. Stock Quote
Fulcrum Therapeutics, Inc.
FULC
$6.85 (0.15%) $0.01
Vertex Pharmaceuticals Stock Quote
Vertex Pharmaceuticals
VRTX
$312.98 (-1.01%) $-3.18
CRISPR Therapeutics Stock Quote
CRISPR Therapeutics
CRSP
$54.99 (-0.07%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.